| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2023 ( Subtotal = $2,626,074 ) |
| | 2023 | 2023 | DIGNITY HEALTH | 185 BERRY ST STE 300 | SAN FRANCISCO | CA | 94107-1773 | SAN FRANCISCO | USA | F32DK130535 | Circadian Regulation of the Dorsomedial Hypothalamic Nucleus and Its Impact on Energy Homeostasis | 001 | 2 | NIH | 3/7/2023 | $1,918 |
| | 2023 | 2023 | DIGNITY HEALTH | 185 BERRY ST STE 300 | SAN FRANCISCO | CA | 94107-1773 | SAN FRANCISCO | USA | R01NS124575 | Multi-scale functional connectivity in preclinical models of Parkinson's disease | 001 | 2 | NIH | 1/31/2023 | $39,938 |
| | 2023 | 2023 | DIGNITY HEALTH | 185 BERRY ST STE 300 | SAN FRANCISCO | CA | 94107-1773 | SAN FRANCISCO | USA | F32DK130535 | Circadian Regulation of the Dorsomedial Hypothalamic Nucleus and Its Impact on Energy Homeostasis | 000 | 2 | NIH | 11/29/2022 | $67,582 |
| | 2023 | 2023 | DIGNITY HEALTH | 185 BERRY ST STE 300 | SAN FRANCISCO | CA | 94107-1773 | SAN FRANCISCO | USA | R01NS124575 | Multi-scale functional connectivity in preclinical models of Parkinson's disease | 000 | 2 | NIH | 11/9/2022 | $359,442 |
| | 2023 | 2023 | DIGNITY HEALTH | 185 BERRY ST STE 300 | SAN FRANCISCO | CA | 94107-1773 | SAN FRANCISCO | USA | R01NS109584 | Mechanisms for intracranial aneurysm rupture | 001 | 4 | NIH | 1/31/2023 | $38,732 |
| | 2023 | 2023 | DIGNITY HEALTH | 185 BERRY ST STE 300 | SAN FRANCISCO | CA | 94107-1773 | SAN FRANCISCO | USA | R01NS109584 | Mechanisms for intracranial aneurysm rupture | 000 | 4 | NIH | 12/2/2022 | $348,598 |
| | 2023 | 2022 | DIGNITY HEALTH | 185 BERRY ST STE 300 | SAN FRANCISCO | CA | 94107-1773 | SAN FRANCISCO | USA | R01AG059008 | MCLENA-1: A Clinical Trial for the Assessment of Lenalidomide in Amnestic MCI Patients | 003 | 4 | NIH | 2/3/2023 | $1,022,207 |
| | 2023 | 2022 | DIGNITY HEALTH | 185 BERRY ST STE 300 | SAN FRANCISCO | CA | 94107-1773 | SAN FRANCISCO | USA | R01ES021488 | Imaging Biomarkers of Neurotoxicity in Welders | 001 | 8 | NIH | 2/10/2023 | $526,094 |
| | 2023 | 2022 | DIGNITY HEALTH | 185 BERRY ST STE 300 | SAN FRANCISCO | CA | 94107-1773 | SAN FRANCISCO | USA | R01AG073212 | Repurposing Siponimod for Alzheimer's Disease | 000 | 2 | NIH | 11/23/2022 | $0 |
| | 2023 | 2022 | DIGNITY HEALTH | 185 BERRY ST STE 300 | SAN FRANCISCO | CA | 94107-1773 | SAN FRANCISCO | USA | R01AG073212 | Repurposing Siponimod for Alzheimer's Disease | 002 | 2 | NIH | 2/3/2023 | $731,856 |
| | 2023 | 2022 | DIGNITY HEALTH | 185 BERRY ST STE 300 | SAN FRANCISCO | CA | 94107-1773 | SAN FRANCISCO | USA | R01AG059008 | MCLENA-1: A Clinical Trial for the Assessment of Lenalidomide in Amnestic MCI Patients | 003 | 4 | NIH | 2/3/2023 | $402,379 |
| | 2023 | 2021 | DIGNITY HEALTH | 185 BERRY ST STE 300 | SAN FRANCISCO | CA | 94107-1773 | SAN FRANCISCO | USA | R01DK108798 | Alpha-synuclein aggregation disrupts motility, synaptic transmission, and calcium signaling in the myenteric plexus of the rat colon | 000 | 5 | NIH | 2/1/2023 | $0 |
| | 2023 | 2021 | Dignity Health | 185 Berry St Ste 300 | San Francisco | CA | 94107-1773 | SAN FRANCISCO | USA | 1P1CMS331609 | Accountable Health Communities, Track 3Dignity SJHMC 2MATCH Project | 03 | 5 | CMS | 12/1/2022 | -$293,771 |
| | 2023 | 2021 | DIGNITY HEALTH | 185 BERRY ST STE 300 | SAN FRANCISCO | CA | 94107-1773 | SAN FRANCISCO | USA | UG3CA247606 | Multi-parametric Perfusion MRI for Therapy Response Assessment in Brain Cancer | 000 | 2 | NIH | 12/7/2022 | $0 |
| | 2023 | 2021 | DIGNITY HEALTH | 185 Berry St Ste 300 | San Francisco | CA | 94107-1773 | SAN FRANCISCO | USA | H7600510 | Ryan White Part C Outpatient EIS Program | 01 | 24 | HRSA | 3/14/2023 | -$78,516 |
| | 2023 | 2021 | DIGNITY HEALTH | 185 BERRY ST STE 300 | SAN FRANCISCO | CA | 94107-1773 | SAN FRANCISCO | USA | R01DA043567 | Prototoxin Effects on Nicotinic Receptor Function | 000 | 4 | NIH | 2/28/2023 | -$333,038 |
| | 2023 | 2020 | DIGNITY HEALTH | 185 BERRY ST STE 300 | SAN FRANCISCO | CA | 94107-1773 | SAN FRANCISCO | USA | R01CA213158 | Establishing the validity of brain tumor perfusion imaging | 000 | 4 | NIH | 3/13/2023 | -$64,571 |
| | 2023 | 2020 | Dignity Health | 185 Berry St Ste 300 | San Francisco | CA | 94107-1773 | SAN FRANCISCO | USA | 1P1CMS331609 | Accountable Health Communities, Track 3Dignity SJHMC 2MATCH Project | 03 | 5 | CMS | 12/1/2022 | $0 |
| | 2023 | 2020 | DIGNITY HEALTH | 185 BERRY ST STE 300 | SAN FRANCISCO | CA | 94107-1773 | SAN FRANCISCO | USA | R21AG064221 | Development of novel viral vectors to study and treat neuroinflammation | 000 | 2 | NIH | 10/20/2022 | $0 |
| | 2023 | 2020 | DIGNITY HEALTH | 185 BERRY ST STE 300 | SAN FRANCISCO | CA | 94107-1773 | SAN FRANCISCO | USA | R01DA042749 | Relevance of ?-Conotoxin MII Sensitive Nicotinic Receptor Subtypes to Nicotine Addiction | 000 | 4 | NIH | 11/13/2022 | -$124,190 |
| | 2023 | 2019 | Dignity Health | 185 Berry St Ste 300 | San Francisco | CA | 94107-1773 | SAN FRANCISCO | USA | 1P1CMS331609 | Accountable Health Communities, Track 3Dignity SJHMC 2MATCH Project | 03 | 5 | CMS | 12/1/2022 | $0 |
| | 2023 | 2018 | Dignity Health | 185 Berry St Ste 300 | San Francisco | CA | 94107-1773 | SAN FRANCISCO | USA | 1P1CMS331609 | Accountable Health Communities, Track 3Dignity SJHMC 2MATCH Project | 03 | 5 | CMS | 12/1/2022 | $0 |
| | 2023 | 2017 | DIGNITY HEALTH | 185 BERRY ST STE 300 | SAN FRANCISCO | CA | 94107-1773 | SAN FRANCISCO | USA | R01NS082280 | The Role of mast Cells in the Pathophysiology of Intracranial Aneurysm | 000 | 6 | NIH | 10/1/2022 | -$18,587 |
| | 2023 | 2017 | Dignity Health | 185 Berry St Ste 300 | San Francisco | CA | 94107-1773 | SAN FRANCISCO | USA | 1P1CMS331609 | Accountable Health Communities, Track 3Dignity SJHMC 2MATCH Project | 03 | 5 | CMS | 12/1/2022 | $0 |
|
| Issue Date FY: 2022 ( Subtotal = $10,090,661 ) (Continued on the next page) |
| | 2022 | 2022 | DIGNITY HEALTH | 185 BERRY ST STE 300 | SAN FRANCISCO | CA | 94107-1773 | SAN FRANCISCO | USA | R01CA213158 | Establishing the validity of brain tumor perfusion imaging | 003 | 6 | NIH | 9/1/2022 | $319,902 |
| | 2022 | 2022 | DIGNITY HEALTH | 185 BERRY ST STE 300 | SAN FRANCISCO | CA | 94107-1773 | SAN FRANCISCO | USA | R01AG073212 | Repurposing Siponimod for Alzheimer's Disease | 002 | 2 | NIH | 7/26/2022 | $688,670 |
| | 2022 | 2022 | DIGNITY HEALTH | 185 BERRY ST STE 300 | SAN FRANCISCO | CA | 94107-1773 | SAN FRANCISCO | USA | R01AG057708 | Pathways linking neuropsychiatric symptoms with Alzheimer's disease neuroimaging biomarkers and the outcome of incident Mild Cognitive Impairment/ Dementia | 001 | 4 | NIH | 4/21/2022 | $39,469 |
| | 2022 | 2022 | DIGNITY HEALTH | 185 BERRY ST STE 300 | SAN FRANCISCO | CA | 94107-1773 | SAN FRANCISCO | USA | R21NS125535 | Investigating the role of cerebral perfusion in demyelination and repair in multiple sclerosis with MRI | 000 | 1 | NIH | 5/17/2022 | $223,494 |
| | 2022 | 2022 | DIGNITY HEALTH | 185 BERRY ST STE 300 | SAN FRANCISCO | CA | 94107-1773 | SAN FRANCISCO | USA | R21NS130492 | Mechanisms of A-I RNA editing-mediated nuclear export of TDP-43 | 000 | 1 | NIH | 9/19/2022 | $345,566 |
| | 2022 | 2022 | DIGNITY HEALTH | 185 BERRY ST STE 300 | SAN FRANCISCO | CA | 94107-1773 | SAN FRANCISCO | USA | R01NS120331 | Microglia contribution to disease pathogenesis in C9orf72 ALS/FTD | 000 | 2 | NIH | 8/1/2022 | $685,891 |
| | 2022 | 2022 | DIGNITY HEALTH | 185 BERRY ST STE 300 | SAN FRANCISCO | CA | 94107-1773 | SAN FRANCISCO | USA | R01NS120331 | Microglia contribution to disease pathogenesis in C9orf72 ALS/FTD | 000 | 2 | NIH | 8/1/2022 | $145,491 |
| | 2022 | 2022 | DIGNITY HEALTH | 185 BERRY ST STE 300 | SAN FRANCISCO | CA | 94107-1773 | SAN FRANCISCO | USA | R01CA264992 | Establishing the clinical utility of a consensus DSC-MRI Protocol | 000 | 1 | NIH | 2/28/2022 | $765,016 |
| | 2022 | 2022 | DIGNITY HEALTH | 185 BERRY ST STE 300 | SAN FRANCISCO | CA | 94107-1773 | SAN FRANCISCO | USA | R01CA264992 | Establishing the clinical utility of a consensus DSC-MRI Protocol | 001 | 1 | NIH | 4/5/2022 | -$83,742 |
| | 2022 | 2022 | DIGNITY HEALTH | 185 BERRY ST STE 300 | SAN FRANCISCO | CA | 94107-1773 | SAN FRANCISCO | USA | R01HL156891 | Chronic Lung Allograft Dysfunction: Role for Tumor Suppressor LKB1 in Exosomes | 000 | 1 | NIH | 6/13/2022 | $407,004 |
| | 2022 | 2022 | DIGNITY HEALTH | 185 BERRY ST STE 300 | SAN FRANCISCO | CA | 94107-1773 | SAN FRANCISCO | USA | R21NS128550 | Transcriptomic assessment of pathology in PD with dementia and dementia with Lewy Bodies using iPSC neurons and brain tissue of the same individuals | 000 | 1 | NIH | 8/5/2022 | $423,274 |
| | 2022 | 2022 | DIGNITY HEALTH | 185 BERRY ST STE 300 | SAN FRANCISCO | CA | 94107-1773 | SAN FRANCISCO | USA | R61NS119642 | Relaxivity Contrast Imaging as Biomarker of Muscle Degeneration in ALS | 000 | 1 | NIH | 11/30/2021 | $809,219 |
| | 2022 | 2022 | DIGNITY HEALTH | 185 BERRY ST STE 300 | SAN FRANCISCO | CA | 94107-1773 | SAN FRANCISCO | USA | R01NS124575 | Multi-scale functional connectivity in preclinical models of Parkinson's disease | 000 | 1 | NIH | 12/23/2021 | $399,380 |
| | 2022 | 2022 | DIGNITY HEALTH | 185 BERRY ST STE 300 | SAN FRANCISCO | CA | 94107-1773 | SAN FRANCISCO | USA | R21NS125861 | Astrocyte regulation of cortical neurodegeneration in C9orf72 FTD/ALS | 002 | 1 | NIH | 4/22/2022 | -$7,209 |
| | 2022 | 2022 | DIGNITY HEALTH | 185 BERRY ST STE 300 | SAN FRANCISCO | CA | 94107-1773 | SAN FRANCISCO | USA | R21NS125861 | Astrocyte regulation of cortical neurodegeneration in C9orf72 FTD/ALS | 000 | 1 | NIH | 3/21/2022 | $94,296 |
| | 2022 | 2022 | Dignity Health | 185 Berry St Ste 300 | San Francisco | CA | 94107-1773 | SAN FRANCISCO | USA | H7600510 | Ryan White Part C Outpatient EIS Program | 01 | 25 | HRSA | 6/24/2022 | $617,164 |
| | 2022 | 2022 | Dignity Health | 185 Berry St Ste 300 | San Francisco | CA | 94107-1773 | SAN FRANCISCO | USA | H7600510 | Ryan White Part C Outpatient EIS Program | 00 | 25 | HRSA | 4/5/2022 | $205,721 |
| | 2022 | 2022 | DIGNITY HEALTH | 185 BERRY ST STE 300 | SAN FRANCISCO | CA | 94107-1773 | SAN FRANCISCO | USA | R01NS115815 | A Translational Evaluation of Sur1-Trpm4 Imaging Endophenotypes and Genetics to Direct Precision Medicine for Cerebral Edema After Traumatic Brain Injury | 000 | 2 | NIH | 4/21/2022 | $573,513 |
| | 2022 | 2022 | DIGNITY HEALTH | 185 BERRY ST STE 300 | SAN FRANCISCO | CA | 94107-1773 | SAN FRANCISCO | USA | R01NS109382 | EGF-ADAM17 axis in the pathophysiology of intracranial aneurysm | 000 | 4 | NIH | 8/19/2022 | $439,103 |
| | 2022 | 2022 | DIGNITY HEALTH | 185 BERRY ST STE 300 | SAN FRANCISCO | CA | 94107-1773 | SAN FRANCISCO | USA | R01AG059008 | MCLENA-1: A Clinical Trial for the Assessment of Lenalidomide in Amnestic MCI Patients | 001 | 4 | NIH | 8/24/2022 | $663,871 |
| | 2022 | 2022 | DIGNITY HEALTH | 185 BERRY ST STE 300 | SAN FRANCISCO | CA | 94107-1773 | SAN FRANCISCO | USA | R01NS109584 | Mechanisms for intracranial aneurysm rupture | 001 | 3 | NIH | 3/22/2022 | $38,733 |
| | 2022 | 2022 | DIGNITY HEALTH | 185 BERRY ST STE 300 | SAN FRANCISCO | CA | 94107-1773 | SAN FRANCISCO | USA | R01NS109584 | Mechanisms for intracranial aneurysm rupture | 000 | 3 | NIH | 11/24/2021 | $348,597 |
| | 2022 | 2022 | DIGNITY HEALTH | 185 BERRY ST STE 300 | SAN FRANCISCO | CA | 94107-1773 | SAN FRANCISCO | USA | U24NS107204 | Barrow Neurological Institute application to become a NeuroNEXT site. | 001 | 5 | NIH | 6/16/2022 | $324,467 |
| | 2022 | 2022 | DIGNITY HEALTH | 185 BERRY ST STE 300 | SAN FRANCISCO | CA | 94107-1773 | SAN FRANCISCO | USA | R01AG057708 | Pathways linking neuropsychiatric symptoms with Alzheimer's disease neuroimaging biomarkers and the outcome of incident Mild Cognitive Impairment/ Dementia | 000 | 4 | NIH | 11/30/2021 | $355,209 |
|
